PMG
AZN icon

ProVise Management Group’s AstraZeneca AZN Stock Holding History

ProVise Management Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-4,455
Closed -$331K – 304
2014
Q2 		$331K Sell
4,455
-760
-15% -$54.9K 0.07% 252
2014
Q1 		$339K Sell
5,215
-1,207
-19% -$78K 0.08% 224
2013
Q4 		$381K Sell
6,422
-478
-7% -$26K 0.1% 207
2013
Q3 		$359K Sell
6,900
-186
-3% -$9.34K 0.1% 211
2013
Q2 		$335K Buy
+7,086
New +$361K 0.1% 220

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ProVise Management Group's AZN Position: Q3 2014 in Review

ProVise Management Group sold out of AstraZeneca (AZN) in Q3 2014, closing a stake of 4,455 shares — an estimated $331K sold.

ProVise Management Group first reported a position in AZN in Q2 2013 and held it in 5 quarters. The position peaked at $381K in Q4 2013. 402 funds tracked by Wall St. Rank hold AZN as of Q3 2014.

  • ProVise Management Group reported no remaining AstraZeneca position as of Q3 2014 after selling out during the quarter.
  • ProVise Management Group sold 4,455 AstraZeneca shares in Q3 2014, an estimated $331K.
  • ProVise Management Group first reported a position in AstraZeneca in Q2 2013 and held it in 5 quarters.
  • ProVise Management Group's AstraZeneca position peaked at $381K in Q4 2013.
  • 402 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2014.

Based on ProVise Management Group's 13F filing for Q3 2014, filed 10 Nov 2014.